Article Sidebar
Published:
Mar 24, 2026DOI:
10.4314/tjpr.v25i2.2Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Asprosin as a novel biomarker for predicting diabetes mellitus risk in humans
Abstract
Purpose: To compare serum asprosin levels among diabetic patients, insulin-resistant individuals, and healthy controls, and to explore its correlation with glycated hemoglobin (HbA1c), Random Blood Sugar (RBS) and body mass index (BMI).
Methods: The study included 130 participants: 110 patients with diabetes-related metabolic conditions (55 with type 2 diabetes mellitus [G1] and 55 insulin-resistant individuals [G2]) and 20 healthy controls (G3) in Faiha Specialized Diabetes, Endocrine and Metabolism Center (FDEMC) in Basra, Iraq and were divided into two groups: type 2 diabetic patients (G1), insulin-resistant individuals (G2), and another 20 healthy individuals (Control; G3). Serum asprosin levels, HbA1c, body weight (BW), height, and BMI were measured. Statistical analysis included comparisons among groups and least significant difference (LSD) testing.
Results: Serum asprosin levels were significantly higher in diabetes mellitus group (3.48 ± 1.88 ng/mL) than both the insulin-resistant (1.56 ± 1.07 ng/mL) and healthy control groups (1.14 ± 0.70 ng/mL; p < 0.05). Similar trends were observed in HbA1c levels, with diabetes mellitus group having the highest values (9.60 ± 2.35). In comparison to control group, the insulin-resistant and diabetic groups had significantly higher BMI and body weight values (p < 0.05).
Conclusion: Elevated asprosin levels are associated with diabetes mellitus and correlate positively with poor glycemic control and increased BMI. Thus, asprosin may serve as a valuable biomarker for insulin resistance and metabolic dysregulation in diabetes.
